论文部分内容阅读
目的:观察泻肺逐饮经验方治疗肺癌胸腔积液饮停胸胁证的临床疗效。方法:选取本院收治的82例肺癌胸腔积液患者为研究对象,随机分为对照组和观察组各41例。2组均给予中心静脉导管引流,对照组给予卡铂注射液胸腔内注射治疗,观察组在对照组治疗基础上加用泻肺逐饮经验汤治疗,2周为1疗程,2组均连续用药3疗程。治疗后观察2组临床疗效,以及治疗前后肿瘤标志物水平[包括癌胚抗原(CEA)、糖类抗原CA199(CA199)、神经元特异性烯醇化酶(NSE)]和生活质量的变化。结果:治疗后观察组有效率为65.85%,高于对照组的36.59%,差异有统计学意义(P<0.05)。治疗前,2组CEA、CA199和NSE水平比较,差异均无统计学意义(P>0.05)。治疗后,2组CEA、CA199和NSE水平均较治疗前降低(P<0.05),观察组3项肿瘤标志物水平均低于对照组(P<0.05)。治疗前,2组卡氏(KPS)评分比较,差异无统计学意义(P>0.05)。治疗后,2组KPS评分均较治疗前升高(P<0.05),观察组的KPS评分高于对照组(P<0.05)。结论:泻肺逐饮经验方治疗肺癌胸腔积液饮停胸胁证临床疗效显著,能有效改善患者的肿瘤标志物水平和提高生活质量。
Objective: To observe the clinical efficacy of Xiefeiyingyin prescription in treating lung cancer pleural effusion Yinxiexiong card. Methods: 82 patients with pleural effusion of lung cancer admitted to our hospital were selected as study subjects and randomly divided into control group and observation group of 41 cases. Both groups were given central venous catheter drainage, the control group was given carboplatin injection intrathoracic injection treatment, the observation group in the control group based on the treatment plus Xiefei by drink experience soup, 2 weeks for a course of treatment, two groups were continuous medication 3 courses. After treatment, the clinical efficacy of the two groups were observed, and the levels of tumor markers [including carcinoembryonic antigen (CEA), carbohydrate antigen CA199 (CA199) and neuron-specific enolase (NSE)] and the quality of life before and after treatment were observed. Results: After treatment, the effective rate of the observation group was 65.85%, which was higher than that of the control group (36.59%), the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in the levels of CEA, CA199 and NSE between the two groups (P> 0.05). After treatment, the levels of CEA, CA199 and NSE in both groups were lower than those before treatment (P <0.05). The levels of three tumor markers in the observation group were lower than those in the control group (P <0.05). Before treatment, there was no significant difference in KPS scores between the two groups (P> 0.05). After treatment, the scores of KPS in both groups were significantly higher than those before treatment (P <0.05). The KPS scores in the observation group were higher than those in the control group (P <0.05). Conclusion: The clinical efficacy of Xiefeiyingyin prescription in treating lung cancer pleural effusion Yinxiaxiexue syndrome is significant, which can effectively improve the level of tumor markers and improve the quality of life in patients.